Form 4: Decheng Capital Reduces BeyondSpring Stake

Decheng Capital, a significant shareholder and director of BeyondSpring Inc., executed pre-planned sales of ordinary shares in mid-August 2025.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and director of BeyondSpring Inc. (BYSI), sold a total of 54,728 ordinary shares over three days in August 2025.
• On August 18, 2025, 47,668 shares were sold at a weighted average price of $2.03 per share, with prices ranging from $1.85 to $2.04.
• On August 19, 2025, an additional 3,604 shares were sold at a weighted average price of $1.77 per share, with prices ranging from $1.75 to $1.85.
• On August 20, 2025, 3,456 shares were sold at a weighted average price of $1.74 per share, with prices ranging from $1.72 to $1.76.
• These transactions were conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following these sales, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,919,444 ordinary shares.
• Other affiliated entities, Decheng Capital China Life Sciences USD Fund II, L.P. and Decheng Capital Global Healthcare Fund (Master), LP, continue to indirectly beneficially own 1,617,409 and 891,734 ordinary shares, respectively.
• The total indirect beneficial ownership for the Decheng Capital group, including all affiliated funds, is approximately 4,428,587 ordinary shares after these transactions.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to insider selling by a significant shareholder and director. However, the negative impact is somewhat mitigated by the fact that the sales were pre-planned under a Rule 10b5-1 plan and represent a relatively small portion of Decheng Capital's overall holdings in BeyondSpring Inc.

Positives

• The share sales were executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction rather than an opportunistic sale, which can reduce the perception of negative signaling.
• The amount of shares sold represents a relatively small percentage of Decheng Capital's total beneficial ownership in BeyondSpring Inc., suggesting it is not a complete divestment.

Negatives

• A significant shareholder and director reducing their stake can be interpreted by the market as a lack of confidence in the company's near-term prospects.
• The sales occurred at declining prices over the three-day period, from a weighted average of $2.03 to $1.74, which could reflect downward price pressure or a strategic decision to exit at prevailing market rates.

Risks

• Potential negative market perception and downward pressure on BeyondSpring Inc.'s stock price due to insider selling.
• Reduced alignment of interests between a major institutional investor/director and common shareholders as their stake decreases.

Future Outlook

No forward-looking statements or guidance were provided in this filing, as it is an insider transaction report.

Industry Context

This filing is an insider transaction report (Form 4) and does not provide information related to broader industry trends or competitive landscape. It solely details the sale of shares by a significant institutional investor and director.

Related Party Transactions

• The reported sales of ordinary shares by Decheng Capital entities constitute related party transactions, as Decheng Capital is a 10% owner and has a director on the board of BeyondSpring Inc.

Stakeholder Impact

• Shareholders may interpret the insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Employees and other stakeholders might perceive this as a sign of reduced long-term commitment from a major investor.

Key Dates

Recommendation

While insider selling by a significant shareholder and director is typically a negative indicator, the sales were conducted under a pre-arranged 10b5-1 plan, suggesting a planned liquidity event rather than an immediate reaction to new negative information. Furthermore, the shares sold represent a relatively small fraction of Decheng Capital's total beneficial ownership in BeyondSpring Inc. Given these factors, a 'hold' recommendation is appropriate for existing investors, advising caution but not immediate divestment, while new investors might want to await further clarity on the company's operational performance.

Keywords

BeyondSpring, BYSI, Decheng Capital, Insider Selling, Form 4, Share Sale, Equity Transaction, 10b5-1 Plan, Biotechnology, Pharmaceutical